A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT00469352
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to understand whether genes or certain factors in the environment determine how eyes will respond to Lucentis (ranibizumab) treatment. For example, whether having variants within specific genes means that a patient is likely to get better vision from treatment than another patient with different genes.

Key Dates

First listed
May 4, 2007
Start date
May 31, 2007
Status verified
Jul 2011
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

The primary outcome measure is clinical treatment response to intravitreal Lucentis, defined as: 'Clinical stabilization' : stabilization of visual acuity. 'Clinical improvement'; 'Clinical progression' [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Casey Eye Institute, Oregon Health and Science UniversityPortlandOregon97239-

Find similar trials in Portland, OR

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Casey Eye Institute, Oregon Health and Science University· Portland, OR

Related Studies